|
|
 |
|
Viewing report
|
|
|
|
Switzerland Pharmaceuticals and Healthcare Report Q2 2008
Business Monitor International, April 2008, Pages: 70
The Switzerland Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Switzerlands pharmaceuticals and healthcare industry.
Switzerland’s drug market is displaying strong growth and should reach a value of US$5.56bn by 2012, driven by demand for innovative pharmaceuticals. Much of the recent growth has been as a result of drugs that have been on the market for less than two years. This reflects the advanced nature of Switzerland’s drug market and bodes well for future expansion.
Switzerland’s leading pharmaceutical firms Novartis and Roche produced mixed results in 2007, reflecting the current uncertain nature of the global pharmaceutical market. Novartis’s total sales reached US$39.8bn, with net income jumping by 66% to US$11.97bn. Yet in the pharmaceuticals division, which is the firm’s most important business, operating income fell to US$6.08bn, from US$6.7bn in 2006, due primarily to a poor performance in the US. Roche posted strong results, with sales reaching CHF46.13bn (US$46.26bn), an increase of 10%. Much of this top line growth was as a result of a strong performance in its pharmaceuticals business, where sales grew by 11% to CHF36.8bn (US$36.9bn).
The author has included Switzerland’s medical devices market in its forecasts for the first time. This sector is highly developed and was worth approximately US$1.2bn in 2007. By 2012, the market should reach a value of US$1.5bn, representing a compound annual growth rate (CAGR) of around 5%, which is roughly in line with growth in the pharmaceutical market. Like Switzerland’s drug sector, the medical devices industry is characterised by impressive technological standards and a high density of operators. Switzerland retains its position in the Business Environment Ranking for the Western Europe region and remains in second place in global terms. The country’s regulatory structures are superb, while percapita drug expenditure is high. The country’s strong economy and stable political environment is highly beneficial.
Customers who bought this item also bought
Switzerland Pharmaceuticals and Healthcare Report Q1 2009
Switzerland Pharmaceuticals and Healthcare Report Q3 2008
Switzerland Pharmaceuticals and Healthcare Report Q3 2007
The Pharmaceutical Market: Switzerland
Switzerland Pharmaceuticals and Healthcare Report Q4 2009
Switzerland Pharmaceuticals and Healthcare Report Q4 2008
Indonesia Pharmaceuticals and Healthcare Report Q4 2008
Saudi Arabia Pharmaceuticals and Healthcare Report Q3 2008
Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2008
United States Pharmaceuticals and Healthcare Report Q4 2008
South Africa Pharmaceuticals and Healthcare Report Q3 2008
Germany Pharmaceuticals and Healthcare Report Q2 2008
|
|
|
|
